TORONTO, November 14, 2003 -- The controversy over prescription drugs continues as more US border states contemplate supplying their needs through Canadian pharmaceutical marketing firms. The issue has raised many questions about the pharmaceutical industry in Canada including research and development, drug-testing, marketing and international trade issues. York University faculty members are at the forefront of the debate with recent published studies and are available to comment.
Pharmaceutical Marketing and Testing
Dr. Joel Lexchin – Medical doctor and health researcher with the School of Health Policy and Management at York University, Dr. Lexchin has been researching pharmaceutical policy issues for more than 20 years and is regarded as an international expert in the areas of promotion of pharmaceuticals and regulatory approval systems for new drugs. (416) 736-2100 x 22119 jlexchin@yorku.ca
Mary Wiktorowicz – Professor of health administration with the School of Health Policy and Management and the author of a recent study comparing drug-testing policies in Canada, Britain, France and the U.S. Prof. Wiktorowicz can comment on the drug-testing systems used by each country and their impact on public health safety. (416) 736-2100 x 22124 mwiktor@yorku.ca
Pharmaceutical Industry
Irene Henriques – Professor of economics with the Schulich School of Business at York University can comment on the international trade aspects of the drug story and is an expert on the economics of the research and development industry. (416) 736-2100 x 77938 ihenriqu@schulich.yorku.ca
Pharmaceutical Research
Sergey Krylov – Professor of chemistry developing new methods in the design of drugs for the treatment of cancer and Alzheimer ’s disease. He leads the establishment of a new York University-centred initiative, the Institute for New Strategies In Drug Engineering. (416) 736-2100 x 22345 skrylov@yorku.ca
Michael Organ – Professor of chemistry and director of the Combinatorial Chemistry Facility at York University, Prof. Organ can comment on processes for discovering and developing new drugs. (416) 736-5313 organ@yorku.ca
-30-
For further information, please contact:
|
David Fuller |
YU/134/03
